Company Name Semnur Pharmaceuticals
Mailing Address 4970 El Camino Real Los Altos, CA 94022 USA
Company Description Semnur Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.
M&A Terms In consideration for the acquisition, Scintilla will pay Semnur’s equity holders an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of common stock of Sorrento. In addition, additional cash consideration of up to $140 million may be paid by Scintilla to Semnur’s equity holders upon achievement of certain development, product approval and commercial milestones. Following the closing of the announced acquisitions Scintilla will operate as a stand-alone company focused on pain management.